Last week we listened to cancer patients describe what cannabis does for them in their own words. This week we look at the other side of the evidence: what happens when cannabinoids are tested for mental health conditions in proper clinical trials.
Cannabis and Mental Health — What 54 Clinical Trials Actually Show
Anxiety, sleep, depression and PTSD are among the top reasons people reach for medical cannabis. A major 2026 review in The Lancet Psychiatry pooled every randomised trial it could find on cannabinoids for mental health and addiction. Some results were encouraging, some were surprising, and one gap is hard to believe.
Ask around any braai and you'll hear it: a joint to take the edge off, a few drops of CBD to quiet a racing mind, something at night to finally sleep. Mental health is one of the biggest reasons people turn to cannabis. In the USA and Canada, 27% of people aged 16 to 65 say they've used cannabis for medical reasons, and half of them did so for their mental health. In Australia, where medical cannabis is prescribed, mental health conditions make up six of the ten most common reasons. So here's the question that matters: when cannabinoids are tested properly, which of those uses hold up?
The Study: 54 Trials, One Big Question
The review was led by Dr Jack Wilson at the University of Sydney's Matilda Centre for Research in Mental Health and Substance Use, with researchers from the University of Queensland, Monash University and the University of Bath. It was published in The Lancet Psychiatry in 2026, one of the most respected journals in the field.
The team only included randomised controlled trials, the gold standard of medical evidence. In a randomised trial, people are split by chance into two groups: one gets the cannabinoid, the other gets a placebo or another comparison. Because chance decides who gets what, any difference in results is far more likely to come from the treatment itself than from hope, habit or coincidence.
They searched every major medical database for trials published between 1980 and May 2025 where a mental health condition or addiction was the main thing being treated. They found 54 trials with 2,477 participants. CBD was the most-tested cannabinoid (24 trials), followed by THC (18) and combinations of the two (12). Treatment lasted about five weeks on average, and the typical trial had around 32 people.
Condition by Condition: The Evidence Scorecard
Here's what the pooled trials found for every condition the review covered. "Certainty" is the researchers' rating of how much confidence the evidence deserves, using a standard system called GRADE.
Where Cannabinoids Showed Promise
Four conditions came out with at least some evidence of benefit, and the authors call these findings encouraging, particularly because good treatment options for them are scarce.
"Most of the benefits came from products combining CBD and THC, not from either cannabinoid on its own."
That pattern will interest anyone who has heard growers and users talk about whole-plant effects. The authors don't claim to know why, and with so few trials in each group, nobody can say for sure. It's another reason the next generation of trials needs to compare cannabinoids head to head.
The Surprises: Anxiety, PTSD, Psychosis and Depression
The biggest surprises are the conditions people most often use cannabis for. Sleep problems, anxiety, depression and PTSD are among the leading reasons for medical use in North America and Australia. Yet the trials found no significant effect for anxiety or PTSD, and there are no trials for depression at all. Of those four, only sleep has trial evidence pointing in a helpful direction.
Psychosis is a striking case. Earlier reviews had flagged CBD as a promising add-on treatment for schizophrenia, and plenty of people still assume it is. Pooling eight trials, mostly of CBD, this review found no significant effect on symptoms.
Safety: More Side Effects, Not More Serious Ones
Overall, people taking cannabinoids had 75% higher odds of experiencing any side effect than those on placebo. Put another way, for every seven people treated, one extra person had a side effect. In the sleep trials, the most common were dry mouth, nausea, diarrhoea and dizziness. The reassuring part: serious side effects and people dropping out of trials were no more common than with placebo.
There's an important catch. Most of these trials used registered, pharmaceutical-grade products such as Sativex, not the high-THC flower, vapes and extracts that fill dispensaries and informal markets. The authors warn that high-THC products could carry risks, including developing cannabis use disorder, that a five-week trial wouldn't pick up. That's why they say public messaging should stress the importance of tested products, a theme we covered in Know Your Herb.
Talk to a doctor or mental health professional about it, and don't drop a treatment that's working. The authors' biggest worry is that cannabis could delay or replace treatments with strong evidence, such as cognitive behavioural therapy, which has shown large benefits for depression and anxiety. Know what's in your product and how much THC it carries. If you're struggling, the South African Depression and Anxiety Group (SADAG) offers free support.
What This Means for South Africa
South Africa's cannabis market is growing quickly, and plenty of people are already using cannabis to manage stress, sleep and mood, often without any guidance. This review is a useful reality check, and its recommendations translate well here. The authors call for health workers to be trained on the real risks and benefits of cannabinoid medicines, for prescribers to have an up-to-date evidence database by condition and product, for less industry funding and better reporting in trials, and for bigger, more representative studies.
They also make a point that cuts both ways: public messaging should avoid both the old scare stories and the new hype, because negative and positive expectations alike can shape how people feel on cannabis. That's the space a community like ours can fill: honest about what the evidence shows, curious about what it doesn't show yet, and focused on the plant rather than the marketing. If you want to understand why scientists expected cannabis to affect mood in the first place, our piece on anandamide, the "bliss molecule" explains the endocannabinoid system behind it.
Quick Answers: Cannabis and Mental Health
Does CBD help with anxiety?
The 2026 Lancet Psychiatry review pooled six clinical trials of cannabinoids for anxiety disorders and found no significant effect on anxiety symptoms. The trial results were too inconsistent to draw a reliable conclusion either way.
Does cannabis help with depression?
Nobody knows yet from clinical trials. The review found no randomised controlled trials testing cannabinoids as a treatment for depression, even though depression is one of the main reasons people report using medical cannabis.
Can cannabis help you sleep?
In four trials of people with insomnia, cannabinoids increased total sleep time, measured by both a wearable device and a sleep diary. The device result was the only benefit in the whole review rated moderate certainty. Overall insomnia symptom scores and sleep quality didn't change significantly, and side effects were common.
Does CBD help PTSD?
Three clinical trials of cannabinoids for post-traumatic stress disorder found no significant effect on PTSD symptoms compared with placebo.
Does CBD help schizophrenia or psychosis?
Eight trials, mostly testing CBD, found no significant effect on overall, positive or negative symptoms of schizophrenia and other psychotic disorders compared with placebo.
What are the side effects of cannabinoids for mental health conditions?
For every seven people treated, one extra person had a side effect compared with placebo. In the sleep trials, the most common were dry mouth, nausea, diarrhoea and dizziness. Serious side effects and dropping out of trials were no more common than with placebo.
Proactive Resilience: Knowledge Is Its Own Kind of Medicine
It would be easy to read this review as bad news for cannabis. It isn't. It's the clearest map yet of where cannabinoids have earned a place in mental health and where they haven't been properly tested. There are real bright spots: better sleep, calmer tics, and a promising route out of problem cannabis use itself, all from medicines that didn't raise the risk of serious harm. And there are big open questions, like depression, that deserve real trials rather than guesswork.
For the cannabis community, that's a strong position to be in. You can enjoy and respect this plant while being honest about what it does and doesn't do, and that honesty is exactly what wins the argument for proper research, proper regulation and proper access. Stay curious, ask for tested products, keep your doctor in the loop, and keep following the evidence as those 14 ongoing trials report back. The more we know, the better every one of us can use this plant.
